Le Dr Alassane Ndiaye, du PEV du Sénégal, présente les progrès du pays dans l’intégration de la vaccination contre le HPV à la vaccination de routine. Depuis l’introduction en 2018, le vaccin est administré au niveau des structures sanitaires, en milieu scolaire et au niveau communautaire, avec un suivi des couvertures de 2025 à mi-2026. […]
Country: Senegal
Country Update – Senegal: Routinising HPV vaccination within the EPI
Dr Alassane Ndiaye of Senegal’s EPI presents the country’s progress in embedding HPV vaccination into routine immunisation. Since the 2018 introduction, the vaccine has been delivered through health facilities, schools, and community outreach, with coverage tracked from 2025 into mid-2026. The update reviews implementation of the national action plan drafted at CHIC 2025 Nairobi, focusing […]
Barriers to HPV vaccine introduction and revitalization in sub-Saharan francophone African countries – A qualitative descriptive study
The pace of progress of HPV vaccine introduction in Sub-Saharan francophone African countries has been limited, particularly in conflict-affected countries. To better understand the barriers affecting the introduction and sustainability of the HPV vaccine, we conducted a qualitative study from January – April 2024 informed by insights from a multi-country HPV symposium. Our study explored […]
Integrating HPV vaccine service delivery with adolescent health programmes – Experiences and perspectives from selected countries in Africa
In this case series, Ndiaye and colleagues describe how Senegal, Togo, Tanzania, and Lesotho have operationalized integrated HPV vaccine service delivery with adolescent health programmes. Across four countries, three models of integration emerge: incorporation into routine immunisation, co-delivery with non-vaccine adolescent health services (e.g., nutrition, deworming, sexual and reproductive health education), and leveraging new vaccine […]
Pandemic-related resilience in HPV vaccination programmes – Perspectives from selected countries in Africa on what it will take to vaccinate 90% of girls by 2030
In this series of five country case studies, Kouassi and colleagues document how Côte d’Ivoire, Kenya, Liberia, Zambia, and Senegal maintained and recovered their HPV vaccination programmes following COVID-19 disruptions. Common challenges included school closures, misinformation conflating HPV and COVID-19 vaccines, and competing health priorities that diverted staff and funding. Enabling factors included strong Ministry […]
Mettre en lumière les défis: expériences nationales d’amélioration de la prestation de services face aux obstacles persistants – Senegal
Au Sénégal, la vaccination contre le HPV a été introduite en 2018 et intégrée dès le départ dans le PEV de routine, avec une offre déployée au niveau des structures sanitaires, des écoles et des communautés. Malgré une couverture de 90 % pour la première dose en 2019, les perturbations liées à la COVID-19 ont […]
Panorama situationnel du HPV – Senegal
Au Sénégal, le vaccin HPV a été introduit à l’échelle nationale en 2018, ciblant les filles de 9 ans avec un schéma Gardasil quadrivalent à 2 doses espacées de 6 mois, et un rattrapage passif pour les 10–14 ans. La couverture nationale s’établit à 68 % pour HPV1 et 34 % pour HPV2 (juillet 2025), […]
Articulating the challenges: Country experiences improving service delivery through a lens of persistent challenges – Senegal
In Senegal, HPV vaccination was introduced in 2018 and integrated from the outset into routine immunization, delivered through health facilities, schools, and community outreach. Despite achieving 90% first-dose coverage in 2019, coverage declined following COVID-19-related disruptions and has since stabilized at around 70%, prompting a national revitalization plan launched in 2023. The country has developed […]
Country Snapshot – Senegal
In Senegal, the HPV vaccine was introduced nationwide in 2018, targeting 9-year-old girls using a quadrivalent Gardasil two-dose schedule (6 months apart) with passive catch-up for girls aged 10–14. National coverage stands at 68% for HPV1 and 34% for HPV2 (July 2025), still below the pre-COVID peak of 90% HPV1 coverage achieved in 2019. Delivery […]
Présentation des discussions au reste du groupe – Groupe 1
Le groupe a identifié deux défis majeurs : atteindre les zones en conflit et renforcer l’adhésion des acteurs clés (enseignants, agents de santé). Il est nécessaire de lutter contre la désinformation, mieux diffuser les données scientifiques et impliquer le système éducatif. Les opportunités incluent l’engagement politique, la participation de la société civile, l’intégration avec d’autres […]